Analyzing RxSight (NASDAQ:RXST) and Microbot Medical (NASDAQ:MBOT)

Microbot Medical (NASDAQ:MBOT) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Risk and Volatility

Microbot Medical has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Insider & Institutional Ownership

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 4.7% of Microbot Medical shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Microbot Medical and RxSight’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
RxSight	-36.58%	-17.01%	-15.12%

Earnings & Valuation

This table compares Microbot Medical and RxSight”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14 million	($0.26)	-6.58
RxSight	$134.48 million	1.60	-$38.94 million	($1.13)	-4.59

Microbot Medical has higher earnings, but lower revenue than RxSight. Microbot Medical is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Microbot Medical and RxSight, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1	0	2	2	3.00
RxSight	3	7	2	0	1.92

Microbot Medical currently has a consensus price target of $6.62, indicating a potential upside of 287.43%. RxSight has a consensus price target of $8.89, indicating a potential upside of 71.27%. Given Microbot Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Microbot Medical is more favorable than RxSight.

Summary

RxSight beats Microbot Medical on 7 of the 13 factors compared between the two stocks.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

About RxSight

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.